Breakthrough in Cancer Gene Therapy: Complete Remission Achieved with Adoptive Immunotherapy

Strategic Insights -

In a remarkable case, a patient with advanced renal cell carcinoma (RCC) achieved complete remission after undergoing adoptive immunotherapy using activated autologous gammadelta T-cells. The 2-year remission milestone, with no additional treatment required, is a significant breakthrough in cancer gene therapy. Researchers at Tokyo Women's Medical University, led by H. Kobayashi, report this impressive outcome in the journal Anticancer Research. Their study demonstrates the potential of gammadelta T-cells as a therapeutic option for patients with advanced RCC.

Key Takeaways:

  • The patient underwent six cycles of adoptive immunotherapy using autologous in vitro-activated gammadelta T-cells, followed by low-dose interleukin-2 and zoledronic acid intravenous infusion.
  • Immunological analysis revealed a high level of interferon-gamma four hours through one day following the transfer and peripheral blood gammadelta T-cells increased 10-fold from the baseline value, 7 days after the transfer.
  • No serious adverse events were observed during the treatment.
  • The patient achieved complete remission, maintained for 2 years without any additional treatment.
  • The adoption of this therapy may offer a new hope for patients with advanced RCC.
  • The study demonstrates the effectiveness and safety of adoptive immunotherapy using gammadelta T-cells.
  • This breakthrough paves the way for further research and development of novel cancer immunotherapy approaches.

Statistics:

  • 2 years: The duration of the patient's remission without additional treatment.
  • 6 cycles: The number of adoptive immunotherapy sessions the patient underwent.
  • 10-fold: The increase in peripheral blood gammadelta T-cells 7 days after the transfer.
  • 4-24 hours: The time frame in which a high level of interferon-gamma was detected following the transfer.
  • 2 years remission: The duration of complete remission achieved by the patient.

Sources:

  • H. Kobayashi et al. (2010). Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Research, 30(2), 575-579.